Research programme: autoimmune disorder and cancer therapeutics - Yuhan

Drug Profile

Research programme: autoimmune disorder and cancer therapeutics - Yuhan

Alternative Names: YH NCE2; YH NCE3

Latest Information Update: 27 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yuhan
  • Class Antineoplastics; Antipsoriatics; Eye disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Graves ophthalmopathy; Psoriasis
  • Research Liver cancer; Lung cancer

Most Recent Events

  • 27 Apr 2018 Early research in Liver cancer in South Korea (unspecified route) (Yuhan pipeline, April 2018)
  • 27 Apr 2018 Early research in Lung cancer in South Korea (unspecified route) (Yuhan pipeline, April 2018)
  • 14 Jan 2016 Preclinical trials in Graves ophthalmopathy in South Korea (unspecified route) before January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top